
Rahul Arora of Nirmal Bang has recommended a blue-chip large-cap Pharma stock which has fallen from favour owing to USFDA issues. He claims that profits of the Company can “triple” and that the time is now opportune to buy the stock
After Shankar Sharma’s clarion call that small-cap stocks will give up to 300% gains in the next three years, the onus is on us to identify these stocks. Luckily, seven top-quality small-cap stocks have been handed over to us on a platter by ET
NAMO has been flayed by the intelligentsia for the handling of the JNU-Kanhaiya affair and the EPF-tax fiasco. However, it is possible that both of these issues are actually red herrings designed to distract the opposition and divert their attention from more pressing issues. The ace stock pickers also appear to have fallen victim to NAMO’s gambit
Saurabh Mukherjea and Andrew Holland, both top-brass at Ambit Capital, appear to be indulging in reckless guesswork in predicting the state of the market. While Andrew Holland has predicted that the Nifty will surge to 10,000 by December 2015, Saurabh Mukherjea has predicted that the Sensex will crash to 22,000 by the same time. This farce has irked the punters at MMB and they have demanded accountability from both stalwarts
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Rakesh Jhunjhunwala
Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala
Recent Comments